Literature DB >> 32647212

Possible drugs for the treatment of bacterial infections in the future: anti-virulence drugs.

Hiroshi Ogawara1,2.   

Abstract

Antibiotic resistance is a global threat that should be urgently resolved. Finding a new antibiotic is one way, whereas the repression of the dissemination of virulent pathogenic bacteria is another. From this point of view, this paper summarizes first the mechanisms of conjugation and transformation, two important processes of horizontal gene transfer, and then discusses the approaches for disarming virulent pathogenic bacteria, that is, virulence factor inhibitors. In contrast to antibiotics, anti-virulence drugs do not impose a high selective pressure on a bacterial population, and repress the dissemination of antibiotic resistance and virulence genes. Disarmed virulence factors make virulent pathogens avirulent bacteria or pathobionts, so that we human will be able to coexist with these disarmed bacteria peacefully.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32647212     DOI: 10.1038/s41429-020-0344-z

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  165 in total

1.  Further observations on penicillin. 1941.

Authors:  E P Abraham; E Chain; C M Fletcher; H W Florey; A D Gardner; N G Heatley; M A Jennings
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Natural product discovery: past, present, and future.

Authors:  Leonard Katz; Richard H Baltz
Journal:  J Ind Microbiol Biotechnol       Date:  2016-01-06       Impact factor: 3.346

Review 3.  Drugs for bad bugs: confronting the challenges of antibacterial discovery.

Authors:  David J Payne; Michael N Gwynn; David J Holmes; David L Pompliano
Journal:  Nat Rev Drug Discov       Date:  2006-12-08       Impact factor: 84.694

Review 4.  Evaluation and Management of Penicillin Allergy.

Authors:  Thanai Pongdee; James T Li
Journal:  Mayo Clin Proc       Date:  2018-01       Impact factor: 7.616

Review 5.  Challenges of antibacterial discovery.

Authors:  Lynn L Silver
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 6.  Platforms for antibiotic discovery.

Authors:  Kim Lewis
Journal:  Nat Rev Drug Discov       Date:  2013-05       Impact factor: 84.694

7.  Complete genome sequence of the model actinomycete Streptomyces coelicolor A3(2).

Authors:  S D Bentley; K F Chater; A-M Cerdeño-Tárraga; G L Challis; N R Thomson; K D James; D E Harris; M A Quail; H Kieser; D Harper; A Bateman; S Brown; G Chandra; C W Chen; M Collins; A Cronin; A Fraser; A Goble; J Hidalgo; T Hornsby; S Howarth; C-H Huang; T Kieser; L Larke; L Murphy; K Oliver; S O'Neil; E Rabbinowitsch; M-A Rajandream; K Rutherford; S Rutter; K Seeger; D Saunders; S Sharp; R Squares; S Squares; K Taylor; T Warren; A Wietzorrek; J Woodward; B G Barrell; J Parkhill; D A Hopwood
Journal:  Nature       Date:  2002-05-09       Impact factor: 49.962

8.  Complete genome sequence and comparative analysis of the industrial microorganism Streptomyces avermitilis.

Authors:  Haruo Ikeda; Jun Ishikawa; Akiharu Hanamoto; Mayumi Shinose; Hisashi Kikuchi; Tadayoshi Shiba; Yoshiyuki Sakaki; Masahira Hattori; Satoshi Omura
Journal:  Nat Biotechnol       Date:  2003-04-14       Impact factor: 54.908

9.  Genome sequence of the streptomycin-producing microorganism Streptomyces griseus IFO 13350.

Authors:  Yasuo Ohnishi; Jun Ishikawa; Hirofumi Hara; Hirokazu Suzuki; Miwa Ikenoya; Haruo Ikeda; Atsushi Yamashita; Masahira Hattori; Sueharu Horinouchi
Journal:  J Bacteriol       Date:  2008-03-28       Impact factor: 3.490

10.  A comprehensive genome-scale reconstruction of Escherichia coli metabolism--2011.

Authors:  Jeffrey D Orth; Tom M Conrad; Jessica Na; Joshua A Lerman; Hojung Nam; Adam M Feist; Bernhard Ø Palsson
Journal:  Mol Syst Biol       Date:  2011-10-11       Impact factor: 11.429

View more
  8 in total

Review 1.  Chemically Tuning Resveratrol for the Effective Killing of Gram-Positive Pathogens.

Authors:  Rubén Cebrián; Qian Li; Pablo Peñalver; Efres Belmonte-Reche; María Andrés-Bilbao; Ricardo Lucas; María Violante de Paz; Oscar P Kuipers; Juan Carlos Morales
Journal:  J Nat Prod       Date:  2022-05-27       Impact factor: 4.803

2.  A phage protein-derived antipathogenic peptide that targets type IV pilus assembly.

Authors:  In-Young Chung; Bi-O Kim; Ju-Hyun Han; Jonggwan Park; Hee Kyoung Kang; Yoonkyung Park; You-Hee Cho
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

Review 3.  Polymyxins, the last-resort antibiotics: Mode of action, resistance emergence, and potential solutions.

Authors:  Saswat S Mohapatra; Sambit K Dwibedy; Indira Padhy
Journal:  J Biosci       Date:  2021       Impact factor: 1.826

4.  Targeting the Pseudomonas aeruginosa Virulence Factor Phospholipase C With Engineered Liposomes.

Authors:  Heidi Wolfmeier; Samuel J T Wardell; Leo T Liu; Reza Falsafi; Annette Draeger; Eduard B Babiychuk; Daniel Pletzer; Robert E W Hancock
Journal:  Front Microbiol       Date:  2022-03-18       Impact factor: 5.640

5.  Repurposing epigenetic inhibitors to target the Clostridioides difficile-specific DNA adenine methyltransferase and sporulation regulator CamA.

Authors:  Jujun Zhou; John R Horton; Dan Yu; Ren Ren; Robert M Blumenthal; Xing Zhang; Xiaodong Cheng
Journal:  Epigenetics       Date:  2021-09-15       Impact factor: 4.861

Review 6.  Antibiotic Therapy of Plague: A Review.

Authors:  Florent Sebbane; Nadine Lemaître
Journal:  Biomolecules       Date:  2021-05-12

7.  Metabolite Profiling of Malaysian Gracilaria edulis Reveals Eplerenone as Novel Antibacterial Compound for Drug Repurposing Against MDR Bacteria.

Authors:  Ali Asghar; Yong-Chiang Tan; Muhammad Shahid; Yoon-Yen Yow; Chandrajit Lahiri
Journal:  Front Microbiol       Date:  2021-06-30       Impact factor: 5.640

8.  Candidates for Repurposing as Anti-Virulence Agents Based on the Structural Profile Analysis of Microbial Collagenase Inhibitors.

Authors:  Georgiana Nitulescu; George Mihai Nitulescu; Anca Zanfirescu; Dragos Paul Mihai; Daniela Gradinaru
Journal:  Pharmaceutics       Date:  2021-12-28       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.